Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173 is registered in ClinicalTrials.gov with Aiwu Ruth He, MD as lead sponsor.

NCT NCT04541173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Lead sponsor
Aiwu Ruth He, MD
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2020
Completion date
June 30, 2023
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma